Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | +0.77% | +12.65% | -19.64% |
May. 14 | Jefferies Downgrades Hyperfine to Hold From Buy, Price Target is $0.90 | MT |
May. 13 | Transcript : Hyperfine, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.64% | 64.31M | - | ||
-7.36% | 14.67B | - | ||
-36.98% | 2.85B | C- | ||
-13.74% | 2.51B | - | ||
-14.58% | 1.42B | - | - | |
-.--% | 1.12B | - | - | |
+53.06% | 566M | - | ||
+88.72% | 507M | B+ | ||
+25.55% | 269M | C | ||
-8.57% | 221M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- HYPR Stock
- Ratings Hyperfine, Inc.